 therapi patient metastat malign melanoma phase II studi forty-seven patient metastat malign melanoma cycl u/kg recombin IV hour week dose schedul ident previou lymphokine-activ killer lak cell phase II clinic trial work group patient elig criteria clinic manag guidelin similar previou trial forty-six patient assess respons object respons patient complet respons cr partial respons pr respons lung liver lymph node subcutan site median respons durat month toxic signific patient myocardi infarct patient therapi toxic respons rate single-ag similar combin lak cell previou trial result single-ag therapi schedul signific antimelanoma activ human lak cell peripher blood littl antimelanoma activ dose schedul